219 related articles for article (PubMed ID: 22516457)
1. [Management of metastatic castration-resistant prostate cancer following docetaxel].
Beuzeboc P; Ropert S; Goldwasser F; Zerbib M
Bull Cancer; 2012 Jul; 99 Suppl 1():S66-72. PubMed ID: 22516457
[TBL] [Abstract][Full Text] [Related]
2. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Metastatic, Castration-resistant, Docetaxel-resistant Prostate Cancer: A Systematic Review of Literature With a Network Meta-analysis of Randomized Clinical Trials.
Tassinari D; Cherubini C; Roudnas B; Tamburini E; Drudi F; Bianchi E; Fantini M; Montanari F; Sartori S
Rev Recent Clin Trials; 2018; 13(3):226-237. PubMed ID: 29623850
[TBL] [Abstract][Full Text] [Related]
4. New treatment options for patients with metastatic prostate cancer.
Snoeks LL; Ogilvie AC; van Haarst EP; Siegert CE
Neth J Med; 2013; 71(6):290-4. PubMed ID: 23956309
[TBL] [Abstract][Full Text] [Related]
5. Novel molecular targets for the therapy of castration-resistant prostate cancer.
Agarwal N; Sonpavde G; Sternberg CN
Eur Urol; 2012 May; 61(5):950-60. PubMed ID: 22209376
[TBL] [Abstract][Full Text] [Related]
6. Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities.
Payne H; Bahl A; Mason M; Troup J; De Bono J
BJU Int; 2012 Sep; 110(5):658-67. PubMed ID: 22429837
[TBL] [Abstract][Full Text] [Related]
7. Management of docetaxel failures in metastatic castrate-resistant prostate cancer.
Pal SK; Lewis B; Sartor O
Urol Clin North Am; 2012 Nov; 39(4):583-91. PubMed ID: 23084533
[TBL] [Abstract][Full Text] [Related]
8. [Management of enzalutamide, a new hormonal therapy].
Beuzeboc P; Benderra MA; de La Motte Rouge T
Bull Cancer; 2014 Jan; 101(1):107-12. PubMed ID: 24491670
[TBL] [Abstract][Full Text] [Related]
9. The androgen receptor, androgen synthesis, and new designer antiandrogens for metastatic castration-resistant prostate cancer: teaching old dogs new tricks.
Lieberman R
Am J Ther; 2013; 20(2):128-31. PubMed ID: 23466618
[No Abstract] [Full Text] [Related]
10. Therapies for castration-resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines.
Mizokami A; Kadono Y; Kitagawa Y; Izumi K; Konaka H
Int J Urol; 2017 Aug; 24(8):566-572. PubMed ID: 28577511
[TBL] [Abstract][Full Text] [Related]
11. [Monitoring of treatment for metastatic castration-resistant prostate cancer].
Hinz S
Aktuelle Urol; 2017 May; 48(3):225-229. PubMed ID: 28614883
[TBL] [Abstract][Full Text] [Related]
12. Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer.
Peters ML; de Meijer C; Wyndaele D; Noordzij W; Leliveld-Kors AM; van den Bosch J; van den Berg PH; Baka A; Gaultney JG
Appl Health Econ Health Policy; 2018 Feb; 16(1):133-143. PubMed ID: 28866822
[TBL] [Abstract][Full Text] [Related]
13. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
[TBL] [Abstract][Full Text] [Related]
14. Combination radium-223 therapies in patients with bone metastases from castration-resistant prostate cancer: A review.
Cursano MC; Iuliani M; Casadei C; Stellato M; Tonini G; Paganelli G; Santini D; De Giorgi U
Crit Rev Oncol Hematol; 2020 Feb; 146():102864. PubMed ID: 31986318
[TBL] [Abstract][Full Text] [Related]
15. Overview of the latest treatments for castration-resistant prostate cancer.
Bishr M; Saad F
Nat Rev Urol; 2013 Sep; 10(9):522-8. PubMed ID: 23797341
[TBL] [Abstract][Full Text] [Related]
16. [The treatment of castration-resistant prostate cancer].
Petrányi Á
Magy Onkol; 2012 Dec; 56(4):219-28. PubMed ID: 23236591
[TBL] [Abstract][Full Text] [Related]
17. Sequencing of agents in castration-resistant prostate cancer.
Lorente D; Mateo J; Perez-Lopez R; de Bono JS; Attard G
Lancet Oncol; 2015 Jun; 16(6):e279-92. PubMed ID: 26065613
[TBL] [Abstract][Full Text] [Related]
18. [Strategy in advanced castration-resistant prostate cancer].
Gross-Goupil M; Roca S; Pasticier G; Ravaud A
Bull Cancer; 2012 Jul; 99 Suppl 1():S37-45. PubMed ID: 22522582
[TBL] [Abstract][Full Text] [Related]
19. [2017 ASCO: Complete androgen blockade strikes back].
Penel N
Bull Cancer; 2017; 104(7-8):599-601. PubMed ID: 28688745
[No Abstract] [Full Text] [Related]
20. MDV3100 for the treatment of prostate cancer.
Mukherji D; Pezaro CJ; De-Bono JS
Expert Opin Investig Drugs; 2012 Feb; 21(2):227-33. PubMed ID: 22229405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
